Boulevard reviews the latest media coverage of the Oscar-winning Louisville native in our exclusive Jennifer Lawrence Diary™. Today’s news, rated on a scale of 1-5 stars:
One of Jennifer Lawrence‘s next projects — espionage thriller “Red Sparrow” — is inching forward with reports Australian actor Joel Edgerton is in talks to co-star. The film, scheduled for release November 2017, according to Variety, is based on 33-year CIA veteran Jason Matthews‘ 2013 novel of the same name.
Deadline, which reported Egerton’s negotiations today, describes the plot:
“The book is set in contemporary Russia, and state intelligence officer Dominika Egorova (Lawrence) struggles to survive in the cast-iron bureaucracy of post-Soviet intelligence. Drafted against her will to become a “sparrow,” a trained seductress in the service, Dominika is assigned to operate against Nathaniel Nash (possibly Edgerton), a first-tour CIA officer who handles the agency’s most sensitive penetration of Russian intelligence. The two young intelligence officers collide in a charged atmosphere of trade craft, deception, and inevitably, a sexual attraction that threatens their careers and the security of America’s valuable mole in Moscow.”
The Red Sparrow script has a tenuous connection to one of Lawrence’s previous movies: It’s a rewritten version of one originally by the author of 2013’s “American Hustle.”
Lawrence, now juggling multiple projects, turns 26 on Aug. 15.
Edgerton, 42, played Tom Buchanan in “The Great Gatsby,” the 2013 remake based on the F. Scott Fitzgerald novel set partly in Louisville. Here’s a clip featuring Edgerton and co-stars Leonardo DiCaprio and Carey Mulligan:
KINDRED said second-quarter results came in at the high end of Wall Street’s expectations. Revenues were $1.8 billion and earnings were 23 cents per share (
Despite its bipartisan-looking logo, the Yum unit franchisees’ PAC has been leaning very right for the past eight years, 
On July 21, the DOJ filed a civil antitrust complaint (which we refer to as the DOJ action) against us and Aetna in the U.S. District Court for the District of Columbia, charging that the merger would violate Section 7 of the Clayton Antitrust Act and seeking a permanent injunction that would prevent the Merger. The filing of the DOJ action is delaying, and, if we and Aetna are unsuccessful in defending against or settling the DOJ action, could ultimately prevent, the consummation of the merger. There can be no assurance that we will be successful in defending against or settling the DOJ action or that the merger will be consummated by any particular time, if at all.